ExlService Holdings, Inc. (EXLS)
Live price chart, market sentiment, and community perspectives for ExlService Holdings, Inc. (NASDAQ: EXLS).
Live price chart, market sentiment, and community perspectives for ExlService Holdings, Inc. (NASDAQ: EXLS).
On our desk, we are seeing a fascinating divergence between Wall Street and retail sentiment for EXLS. While 8 out of 9 tracked analysts rate the stock a buy with a strong consensus target, retail chatter across Reddit and X remains remarkably sparse with only 7 mentions over the past week. For our fund, this lack of broad retail hype actually presents a cleaner accumulation profile, as institutional sponsorship drives the underlying price action without emotional sentiment noise.
Looking at the Q2 2026 earnings report for ExlService Holdings, the underlying fundamentals look remarkably solid. Revenue grew 15.6% year-over-year to $594.8 million, while adjusted diluted EPS jumped 22.3% to $0.59. More importantly, data and AI-led revenue surged 30% and now accounts for 61% of total revenue. Management's decision to raise full-year revenue guidance to a range of $2.39 billion to $2.415 billion gives us strong conviction in their forward visibility.
Reviewing the recent integration mechanics of the iMerit acquisition, bringing founder and CEO Radha Ramaswami Basu onto the executive committee as Head of iMerit is a strategic masterstroke. It immediately deepens EXL's in-house AI and data annotation capabilities, strengthening their competitive moat in regulated sectors like insurance and healthcare. We are modeling the contribution of $28 million to $32 million in 2026 revenue directly into our growth projections.
As a data and AI strategist evaluating operational transformations in healthcare and insurance, EXL's structural reorganization into four distinct Industry Market Units—including Healthcare and Life Sciences—deserves close attention. Their ability to move AI projects into production, particularly regarding agentic AI and token optimization, shows they are moving past the pilot phase. However, our technical evaluation notes that increased second-half spending on data management and AI capabilities could pressure near-term operating margins.
From a risk management standpoint, EXLS's 10-K filing outlines a comprehensive risk framework centered on rapid AI deployment, data security, and execution risks across global markets. Even though the filing sentiment is neutral, the detailed operational focus on their new market units shows proactive governance. We are advising portfolio managers to keep an eye on execution risks related to scaling their newly acquired data annotation infrastructure in the second half of the year.
Explore plasma cleansing, somatic organ swaps, and BCI.